Stock NAVA NAVAMEDIC ASA
Add to a list
To use this feature you must be a member
Log inSign up

Navamedic ASA Stock

Equities

NAVA

NO0010205966

Pharmaceuticals

Market Closed - Oslo Bors
Other stock markets
 10:45:00 2024-04-19 am EDT 		5-day change 1st Jan Change
34.1 NOK +1.79% Intraday chart for Navamedic ASA +0.89% -7.08%
Mar. 13 Ingerø Reiten Investment Divests Navamedic Stake in NOK95 Million Deal MT
Mar. 12 An unknown buyer acquired unknown minority stake in Navamedic ASA (OB:NAVA) from Ingerø Reiten Investment Company As for NOK 95 million. CI

Financials

Sales 2023 512M 46.5M Sales 2024 * 615M 55.88M Capitalization 594M 53.99M
Net income 2023 3M 272K Net income 2024 * 42M 3.81M EV / Sales 2023 1.46 x
Net Debt 2023 109M 9.85M Net Debt 2024 * 38M 3.45M EV / Sales 2024 * 1.03 x
P/E ratio 2023 *
40.4 x
P/E ratio 2024 *
14.5 x
Employees 45
Yield 2023 *
-
Yield 2024 *
-
Free-Float 58.33%
More Fundamentals * Assessed data

Chart Navamedic ASA

Dynamic Chart

Latest news about Navamedic ASA

Ingerø Reiten Investment Divests Navamedic Stake in NOK95 Million Deal MT
An unknown buyer acquired unknown minority stake in Navamedic ASA (OB:NAVA) from Ingerø Reiten Investment Company As for NOK 95 million. CI
Navamedic ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Navamedic Acquires Rights to Distribute Erectile Dysfunction Treatment in Nordic Countries MT
Navamedic ASA Acquires Rights to Market and Distribute Eroxon in the Nordic Countries CI
Navamedic ASA Renews Contract Signed with Vitaflo International Limited CI
Navamedic Enters Agreement with Orion for Distribution of Parkinson's Drug Across Europe MT
Navamedic ASA and Orion Corporation Sign Non-Binding Term Sheet for Flexilev® in Europe CI
Navamedic ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Navamedic ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Navamedic ASA Elects Åsa Kornfeld as Members of its Board of Directors CI
Navamedic Secures Ownership of Sweden’s Sensidose MT
Navamedic ASA (OB:NAVA) completed the acquisition of Sensidose AB. CI
EQL Pharma Closes Sensidose Bid, to Accept Navamedic Offer MT
Navamedic ASA Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
More news

Press releases Navamedic ASA

Disclosure in NAVAMEDIC ASA AQ
Major shareholder disclosure in Navamedic ASA AQ
Navamedic ASA - Mandatory notification of trade by primary insider AQ
Navamedic ASA: Resolution to increase the share capital in connection with exercise of employee options AQ
Navamedic welcomes new shareholders AQ
More press releases

Quotes and Performance

1 day+1.79%
1 week+0.89%
Current month-4.21%
1 month-2.29%
3 months-12.34%
6 months-17.43%
Current year-7.08%
More quotes

Highs and lows

1 week
32.90
Extreme 32.9
34.70
1 month
32.90
Extreme 32.9
38.30
Current year
32.60
Extreme 32.6
40.00
1 year
31.00
Extreme 31
43.90
3 years
19.50
Extreme 19.5
43.90
5 years
13.05
Extreme 13.05
43.90
10 years
8.00
Extreme 8
43.90
More quotes

Managers and Directors - Navamedic ASA

Managers TitleAgeSince
Kathrine Elisabeth Andreassen CEO
 Chief Executive Officer 58 18-05-31
Lars Hjarrand DFI
 Director of Finance/CFO 51 19-12-08
Astrid T. Bratvedt CTO
 Chief Tech/Sci/R&D Officer - 18-12-31
Members of the board TitleAgeSince
Narve Reiten BRD
 Director/Board Member 63 -
Terje Bakken CHM
 Chairman 58 18-12-30
Jostein Davidsen BRD
 Director/Board Member 65 17-01-15
More insiders

Quotes

Date Price Change Volume
24-04-19 34.1 +1.79% 2,402
24-04-18 33.5 -0.89% 10,636
24-04-17 33.8 -0.29% 437
24-04-16 33.9 +0.89% 12,042
24-04-15 33.6 -0.59% 9,572

Real-time Oslo Bors, April 19, 2024 at 10:45 am EDT

More quotes

Company Profile

Navamedic ASA is a Norway-based pharmaceutical company. It is a supplier of products delivered to hospitals and pharmacies. Navamedic’s product portfolio consists of prescription and Over The Counter (OTC) pharmaceuticals as well as other healthcare products registered as medical nutrition, medical devices, food supplements or cosmetics. The Company’s offering is divided into four product areas: Consumer Health, Specialty Pharma, Medical Nutrition and Branded Generics. The Company has one business segment which is the Pharma division. Navamedic ASA is present in all Nordic countries, the Baltics and Benelux. The Company has two subsidiaries, Navamedic AB, through which the Company distributes more than 40 products and a Norway-based Novicus Pharma AS.
Sector
Pharmaceuticals
Calendar
2024-05-06 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Navamedic ASA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
34.1 NOK
Average target price
51 NOK
Spread / Average Target
+49.56%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
NAVAMEDIC ASA Stock Navamedic ASA
-7.08% 53.99M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+24.60% 654B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.08% 552B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.63% 356B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.37% 319B
ABBVIE INC. Stock AbbVie Inc.
+7.38% 295B
ASTRAZENECA PLC Stock AstraZeneca PLC
+3.26% 211B
NOVARTIS AG Stock Novartis AG
+0.78% 206B
PFIZER, INC. Stock Pfizer, Inc.
-9.69% 147B
AMGEN INC. Stock Amgen Inc.
-6.63% 144B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. NAVA Stock